EMERYVILLE, Calif. (July 27, 2020) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and six months ended June 30, 2020 after market close on Thursday, August 6, 2020 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.
“With completion of the warrant exercise last week we fully expect to regain compliance with our NYSE listing, while raising $6.8 million in gross proceeds to support our business strategy,” said Justin Hall, NovaBay’s CEO. “As announced last week in an SEC filing, we expect second quarter net sales to approximately double from the first quarter, due primarily to sales of KN95 disposable face masks, while operating loss is expected to decline 25% versus the prior quarter. We look forward to providing a more detailed review of our financial results and business progress during our upcoming conference call.”
Conference Call and Webcast
DATE: Thursday, August 6
TIME: 4:30 p.m. ET / 1:30 p.m. PT
DIAL IN: 800-608-8202 from within the U.S
702-495-1913 from outside the U.S.
Enter conference identification number 7662239
The live call also will be available at https://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time August 27, 2020 by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S., and entering conference ID 7662239. The call will also be archived at https://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, CELLERX® for the aesthetic dermatology market and NEUTROPHASE® for the wound care market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
Forward-Looking Statements and Disclaimers
This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to further consumer acceptance of Avenova, and any potential damage to our established goodwill in the marketplace. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay informed on NovaBay’s progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
www.Avenova.com
NovaBay Contact
Justin Hall
President and Chief Executive Officer
510-899-8800
jhall@novabay.com
Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com